Cardiovascular complications of cirrhosis

Gut

Volumn 57, Issue 2, 2008, Pages 268-278

  Moller S ^a,b   Henriksen, J H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN ANTAGONIST; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENOIC ACID; CANRENONE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; NORADRENALIN; OCTREOTIDE; PLASMA SUBSTITUTE; TERLIPRESSIN;

ARTERY DILATATION; ASCITES; AUTONOMIC DYSFUNCTION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DIASTOLIC DYSFUNCTION; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MORTALITY; OXYGEN THERAPY; PARACENTESIS; PERIPHERAL CIRCULATION; PERITONEUM VEIN SHUNT; PLASMA VOLUME; PRESSORECEPTOR; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SODIUM RESTRICTION; SPLANCHNIC BLOOD FLOW; SYSTOLIC DYSFUNCTION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD CIRCULATION; BLOOD PRESSURE; BLOOD VOLUME; CARDIAC OUTPUT; CARDIOVASCULAR DISEASES; DIASTOLE; ELECTROPHYSIOLOGY; EXTREMITIES; HEART DISEASES; HUMANS; LIVER CIRCULATION; LIVER CIRRHOSIS; SYSTOLE; VASODILATION;

EID: 38549172857     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.112177     Document Type: Review

References (83)

1. Møller S, Henriksen JH. The systemic circulation in cirrhosis. In: Gines P, Arroyo V, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease. Malden: Blackwell, 2005:139-55.
2. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S121-31.
3. Trevisani F, Sica G, Mainqua P, et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 1999;30:1387-92.
4. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol 2006;12:837-42.
5. Laffi G, Barletta G, Lavilla G, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997;113:891-8.
6. Møller S, Nørgaard A, Henriksen JH, et al. Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. Hepatology 2004;40:811-9.
7. Brinch K, Møller S, Bendtsen F, et al. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003;39:24-31.
8. Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006;119:S47-S53.
9. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995;109:1917-25.
10. Kiszka-Kanowitz M, Henriksen JH, Møller S, et al. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J Hepatol 2001; 35:605-12.
11. Møller S, Bendtsen F, Christensen E, et al. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. J Hepatol 1994;21:940-6.
12. Hadengue A, Moreau R, Gaudin C, et al. Total effective vascular compliance in patients with cirrhosis: a study of the response to acute blood volume expansion. Hepatology 1992;15:809-15.
13. Henriksen JH, Møller S, Schifter S, et al. High arterial compliance in cirrhosis is related to elevated circulating calcitonin gene-related peptide (CGRP) and low adrenaline, but not to activated vasoconstrctor systems. Gut 2001;49:112-8.
14. Henriksen JH, Fuglsang S, Bendtsen F, et al. Arterial compliance in patients with cirrhosis. High stroke volume/pulse pressure ratio as an index of elevated arterial compliance. Am J Physiol 2001;280:G584-94.
15. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-91.
16. Rodriguez-Roisin R, Krowka MJ, Herve P, et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24:861-80.
17. Møller S, Burchardt H, Ogard CG, et al. Pulmonary blood volume and transit time in cirrhosis: relation to lung function. Liver Int 2006;26:1072-8.
18. Wiest R, Jurzik L, Herold T, et al. Role of NPY for vasoregulation in the splanchnic circulation during portal hypertension. Peptides 2007;28:396-404.
19. Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006;290:G980-7.
20. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46:935-46.
21. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the International Ascites Club. Gut 2007;56:1310-8.
22. Helmy A, Newby DE, Jalan R, et al. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003;52:410-5.
23. Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol 2006;44:209-16.
24. La Villa G, Barletta G, Pantaleo P, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001;34:19-27.
25. Ferguson JW, Dover A, Chia S, et al. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 2005;55:542-6.
26. Fernandez M, Mejias M, Angermayr B, et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005;43:98-103.
27. Bolognesi M, Sacerdoti D, Di Pascoli M, et al. Haeme oxygenase mediates hyporeactive to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut 2005;54:1630-6.
28. Ebrahimkhani MR, Mani AR, Moore K. Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: a hypothesis. Gut 2005;54:1668-71.
29. Hennenberg M, Biecker E, Trebicka J, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006;130:838-54.
30. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001;21:337-49.
31. Møller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001;36:785-94.
32. Gines P, Guevara M, De Las HD, et al. Review article: albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther 2002;16(Suppl 5):24-31.
33. Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-53.
34. Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002;50:90-4.
35. Singh V, Kumar B, Nain CK, et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006;260:62-8.
36. Wong F, Logan A, Blendis L. Hyperinsulinemia in preascitic cirrhosis: effects on systemic and renal hemodynamics, sodium homeostasis, forearm blood flow, and sympathetic nervous activity. Hepatology 1996;23:414-22.
37. Ruiz-Del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-47.
38. Maroto A, Gines P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis - relationship to kidney dysfunction. Hepatology 1993;17:788-93.
39. Luca A, Garcia-Pagan JC, Feu F, et al. Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. Hepatology 1995;21:83-8.
40. Carella M, Hunter JO, Fazio S, et al. Capillary blood flow to the skin of forearm in cirrhosis. Angiology 1992;43:969-74.
41. Helmy A, Newby DE, Jalan R, et al. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J Hepatol 2003;38:44-50.
42. Hendrickse MT, Triger DR. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. Am J Gastroenterol 1994;89:750-7.
43. Dillon JF, Nolan J, Thomas H, et al. The correction of autonomic dysfunction in cirrhosis by captopril. J Hepatol 1997;26:331-5.
44. Ates F, Topal E, Kosar F, et al. The relationship of heart rate variability with severity and prognosis of cirrhosis. Dig Dis Sci 2006;51:1614-8.
45. Mohamed R, Forsey PR, Davies MK, et al. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996;23:1128-34.
46. Grose RD, Nolan J, Dillon JF, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995;22:326-32.
47. Epstein SK, Ciubotaru RL, Zilberberg MD, et al. Analysis of impaired exercise capacity in patients with cirrhosis. Dig Dis Sci 1998;43:1701-7.
48. Villa GL, Barletta G, Romanelli RG, et al. Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology 2002;35:1441-8.
49. Ferlitsch A, Pleiner J, Mittermayer F, et al. Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites. Crit Care Med 2005;33:2028-33.
50. Tripathi D, Therapondos G, Ferguson JW, et al. Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut 2006;55:1290-5.
51. Ros J, Claria J, To-Figueras J, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122:85- 93.
52. Moezi L, Gaskari SA, Liu H, et al. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol 2006;149:898-908.
53. Batkai S, Mukhopadhyay P, Harvey-White J, et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 2007;293:H1689-95.
54. Møller S, Wiinberg N, Henriksen JH. Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology 1995;22:88-95.
55. Wong F, Logan A, Blendis L. Systemic hemodynamic, forearm vascular, renal, and humoral responses to sustained cardiopulmonary baroreceptor deactivation in well-compensated cirrhosis. Hepatology 1995;21:717-24.
56. Laffi G, Lagi A, Cipriani M, et al. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology 1996;24:1063-7.
57. Møller S, Iversen JS, Henriksen JH, et al. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol 2007;292:H2966- 72.
58. Møller S, Søndergaard L, Møgelvang J, et al. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology 1995;22:472-8.
59. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
60. Mani AR, Ippolito S, Ollosson R, et al. Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis. Hepatology 2006;43:847-56.
61. Pacher P, Batkai S, Kunos G. Cirrhotic cardiomyopathy: an endocannabinoid connection? Br J Pharmacol 2005;146:313-4.
62. Gaskari SA, Liu H, Moezi L, et al. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005;146:315-23.
63. Wong F, Girgrah N, Graba J, et al. The cardiac response to exercise in cirrhosis. Gut 2001;49:268-75.
64. Krag A, Bendtsen F, Henriksen JH, et al. Cardiac effects of terlipressin in cirrhosis. Unmasking a cirrhotic cardiomyopathy. J Hepatol 2007;46:S96.
65. Huonker M, Schumacher YO, Ochs A, et al. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999;44:743-8.
66. Merli M, Valeriano V, Funaro S, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002;97:142-8.
67. Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839- 47.
68. Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997;26:1131-7.
69. Torregrosa M, Aguade S, Dos L, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42:68-74.
70. Ruiz-Del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-8.
71. Pozzi M, Redaelli E, Ratti L, et al. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol Dietol 2005;51:179-86.
72. Finucci G, Desideri A, Sacerdoti D, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996;31:279-84.
73. Cazzaniga M, Salerno F, Pagnozzi G, et al. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut 2007;56:869-75.
74. Pozzi M, Grassi G, Ratti L, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 2005;100:1110-6.
75. Bos R, Mougenot N, Findji L, et al. Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. J Cardiovasc Pharmacol 2005;45:8-13.
76. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000;6:S44-52.
77. Karabulut A, Iltumur K, Yalcin K, et al. Hepatopulmonary syndrome and right ventricular diastolic functions: an echocardiographic examination. Echocardiography 2006;23:271-8.
78. Henriksen JH, Fuglsang S, Bendtsen F, et al. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002;36:513-20.
79. Zambruni A, trevisani F, Caraceni P, et al. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006;44:994-1002.
80. Zavecz JH, Bueno O, Maloney RE, et al. Cardiac excitation-contraction coupling in the portal hypertensive rat. Am J Physiol 2000;279:G28-39.
81. Ward CA, Ma Z, Lee SS, et al. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol Gastrointest Liver Physiol 1997;273:G537-44.
82. Henriksen JH, Bendtsen F, Hansen EF, et al. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (OTc) in patients with cirrhosis. J Hepatol 2004;40:239- 46.
83. Henriksen JH, Götze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-7.